About — FinsnoBio

At FinsnoBio we are dedicated to developing the therapeutic potential of the Parkin protein for patients with serious medical conditions. We envision a future where the power of the Parkin pathway is directed toward specific disease areas, where the activation of the repair pathway can have maximum therapeutic benefits. Our core team of industry professionals and network of academic experts are working together to deliver on on the scope of therapeutic potential for Parkin cellular repair. Learn About the Science!

LEADERSHIP

Jennifer A. Johnston, Ph.D. Cofounder and CEO — Jennifer A. Johnston, Ph.D.
*Cofounder and CEO*

Ying Feng Head of Biology Small Molecules — Ying Feng
*Head of Biology Small Molecules*

Sarah Finley Project Management — Sarah Finley
*Project Management*

Steve Lacy Head of Toxicology — Steve Lacy
*Head of Toxicology*

Andrew Phimister Head of Formulations — Andrew Phimister
*Head of Formulations*

Sarah Jaw-Tsai, Ph.D. Head of DMPK — Sarah Jaw-Tsai, Ph.D.
*Head of DMPK*

SCIENTIFIC ADVISORY BOARD

Timothy Chan, M.D., Ph.D. Director, Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic — Timothy Chan, M.D., Ph.D.
*Director, Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic*

Alfred L. Goldberg, Ph.D. - DF/HCC Professor of Cell Biology, Harvard Medical School — Alfred L. Goldberg, Ph.D. - DF/HCC
*Professor of Cell Biology, Harvard Medical School*

Eugene M. Johnson, Jr., Ph.D. Professor Emeritus, Neurology and Developmental Biology, Washington University Medical School, St. Louis, Missouri — Eugene M. Johnson, Jr., Ph.D.
*Professor Emeritus, Neurology and Developmental Biology, Washington University Medical School, St. Louis, Missouri*

Paul Fatheree Scientific Advisor to Small Molecule Programs — Paul Fatheree
Scientific Advisor to Small Molecule Programs